George Belecanech, MD
Allergy & Immunology · Voorhees, NJNPI 1376691626
Payments from drug & device makers
Across 1,136 payments — averaging $182.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$121K
- AstraZeneca$57K
- Boehringer Ingelheim$15K
- Amgen$6K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- CSL Behring$997
- plus $6K from 31 others
What the payments were for
- Consulting fees$2,9051%
- Speaking & faculty fees$181,92588%
- Travel & lodging$2,8221%
- Food & beverage$19,5739%
- Education$2830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 333 | $121,215 |
| AstraZeneca | 241 | $56,788 |
| Boehringer Ingelheim | 54 | $14,766 |
| Amgen(2 entities) | 22 | $6,102 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $1,462 |
| CSL Behring | 71 | $997 |
| Sanofi | 61 | $985 |
| Novartis | 50 | $750 |
| Kaleo, Inc. | 37 | $590 |
| Regeneron Healthcare Solutions, Inc. | 28 | $495 |
| Genentech USA, Inc. | 28 | $442 |
| Biocryst US Sales Co., LLC | 29 | $423 |
| Optinose US, Inc. | 23 | $314 |
| Teva Pharmaceuticals USA, Inc. | 24 | $232 |
| Alk-abello, Inc | 13 | $216 |
| Pfizer | 14 | $200 |
| Covis Pharma GmbH | 11 | $195 |
| AbbVie | 10 | $173 |
| Bio Products Laboratory USA, Inc. | 9 | $152 |
| Mylan Specialty L.p. | 11 | $148 |
| Hikma Pharmaceuticals USA | 9 | $142 |
| Grifols USA, LLC | 5 | $99 |
| Aimmune Therapeutics, Inc. | 7 | $97 |
| Blueprint Medicines Corporation | 5 | $79 |
| Cycle Pharmaceuticals Inc | 3 | $64 |
| Pharming Healthcare, Inc. | 3 | $56 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $48 |
| Octapharma USA, Inc. | 2 | $45 |
| Shire North American Group Inc | 3 | $41 |
| Philips North America LLC | 2 | $38 |
| Galderma Laboratories, L.p. | 2 | $37 |
| Merck | 2 | $27 |
| Eyevance Pharmaceuticals LLC | 2 | $24 |
| Circassia Inc. | 1 | $20 |
| ADMA Biomanufacturing LLC | 1 | $17 |
| USWM, LLC | 1 | $15 |
| Biocryst Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$207,507 in reported general payments places this provider in the 90th percentile of 135 allergy & immunology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 13 | $682,516 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 17 | $210,523 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $94,780 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 98 | $92,392 |
| TezspireTezepelumab-Ekko | 20 | $81,253 |
| Dupixent PenDupilumab | 16 | $60,273 |
| Spiriva RespimatTiotropium Bromide | 44 | $54,392 |
| XolairOmalizumab | 12 | $33,314 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $29,048 |
| SymbicortBudesonide/Formoterol Fumarate | 68 | $26,900 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $24,014 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 55 | $16,020 |
| AlvescoCiclesonide | 14 | $15,087 |
| Arnuity ElliptaFluticasone Furoate | 31 | $14,541 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 168 | $12,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $1,462 | $682,51613 claims |
| Bio Products Laboratory USA, Inc.Gammaplex | $152 | $210,52317 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $121,215 | $140,764171 claims |
| AstraZenecaTezspire, Symbicort, Breztri Aerosphere, Pulmicort Flexhaler | $56,788 | $136,133127 claims |
| CSL BehringHizentra | $997 | $94,78012 claims |
| Boehringer IngelheimSpiriva Respimat | $14,766 | $54,39244 claims |
| Covis Pharma GmbHAlvesco | $195 | $15,08714 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $232 | $11,02916 claims |
| MerckDulera | $27 | $6,46812 claims |
| Hikma Pharmaceuticals USAEpinephrine | $142 | $3,73726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 135 allergy & immunology providers in New Jersey.
Other allergy & immunology in Voorhees
- Sheryl MathewVoorhees$11K
- Ellen SherOcean$2.7M
- Andrew PedinoffSkillman$2.3M
- Bruce DecotiisBrick$647K
- Patrick PerinTeaneck$589K
- Peter RickettiTrenton$501K
- Jinping GuoMarlton$488K
- Mark WeinsteinBelleville$424K
- Tina ZeccaLittle Silver$407K
- John KimMedford$339K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.